Xing Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xing Guo has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Shaobing Zhou
Institute of Biomedical Engineering, College of Medicine, Southwest Jiaotong University, Chengdu, 610031, China
18 shared publications Jingmei Pan
13 shared publicationsZhenhua Wang
Institute of Biomedical Engineering, College of Medicine, Southwest Jiaotong University, Chengdu, PR China
7 shared publicationsJiaoyang Wang
Institute of Biomedical Engineering, College of Medicine
4 shared publicationsMengyi Yang
Institute of Biomedical Engineering, College of Medicine
4 shared publicationsMo Chen
Institute of Biomedical Engineering College of Medicine Southwest Jiaotong University Chengdu P. R. China
4 shared publications
Latest Publications
- 8 October 2026
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 26 (41) , 14491
Correction to “Personalized Nanovaccine Coated with Calcinetin-Expressed Cancer Cell Membrane Antigen for Cancer Immunotherapy”
- 8 October 2026
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 26 (41) , 14491
Correction to “Personalized Nanovaccine Coated with Calcinetin-Expressed Cancer Cell Membrane Antigen for Cancer Immunotherapy”
- Open Access
- 1 June 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 60, 510-526
M2 macrophage-derived exosomes delivering haptoglobin and interleukin-10 plasmids for synergistic therapy of intracerebral hemorrhage
Intracerebral hemorrhage (ICH) carries high mortality and disability rates, driven not only by the initial bleeding but also by secondary neurotoxicity from blood derived components such as hemoglobin. An effective strategy during the subacute phase must therefore address both hematoma clearance and neuroinflammation. To achieve this dual action therapy, we engineered a novel nanoplatform (M2-exo@HI) by encapsulating a plasmid co-expressing haptoglobin (Hp) and interleukin-10 (IL-10) within M2 macrophage-derived exosomes. Leveraging the innate inflammatory homing of macrophage exosomes, M2 exo@HI delivers the HI plasmid to the ICH site, where it is primarily internalized by M1 microglia. The expressed Hp binds hemoglobin, reducing neurotoxicity and exert neuroprotective effects. Simultaneously, IL-10 polarizes M1 microglia to the neuroprotective M2 phenotype, thereby removing hematoma and alleviating neuroinflammation via anti-inflammatory cytokine production. Consequently, M2-exo@HI significantly reduced hematoma volume, improved long-term neurological function, and enhanced blood-brain barrier (BBB) repair. Transcriptome analysis further elucidated the genetic mechanisms underlying this synergistic effect. This work presents a promising co-delivery strategy for enhancing hemorrhagic stroke therapy.
- 1 June 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 60, 510-526
Open AccessM2 macrophage-derived exosomes delivering haptoglobin and interleukin-10 plasmids for synergistic therapy of intracerebral hemorrhage
Intracerebral hemorrhage (ICH) carries high mortality and disability rates, driven not only by the initial bleeding but also by secondary neurotoxicity from blood derived components such as hemoglobin. An effective strategy during the subacute phase must therefore address both hematoma clearance and neuroinflammation. To achieve this dual action therapy, we engineered a novel nanoplatform (M2-exo@HI) by encapsulating a plasmid co-expressing haptoglobin (Hp) and interleukin-10 (IL-10) within M2 macrophage-derived exosomes. Leveraging the innate inflammatory homing of macrophage exosomes, M2 exo@HI delivers the HI plasmid to the ICH site, where it is primarily internalized by M1 microglia. The expressed Hp binds hemoglobin, reducing neurotoxicity and exert neuroprotective effects. Simultaneously, IL-10 polarizes M1 microglia to the neuroprotective M2 phenotype, thereby removing hematoma and alleviating neuroinflammation via anti-inflammatory cytokine production. Consequently, M2-exo@HI significantly reduced hematoma volume, improved long-term neurological function, and enhanced blood-brain barrier (BBB) repair. Transcriptome analysis further elucidated the genetic mechanisms underlying this synergistic effect. This work presents a promising co-delivery strategy for enhancing hemorrhagic stroke therapy.
Tolerogenic Nanovaccine Synergizing Citrullinated Peptide and TSP‐1 Plasmid for Antigen‐Specific Immunotherapy of Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune disorder driven by systemic inflammation and progressive joint damage. While antigen‐specific immune tolerance holds promise as a therapeutic strategy, its clinical translation is hampered by the rapid clearance and unintended immunogenicity associated with conventional antigen delivery. To address these limitations, we developed a tolerogenic nanovaccine (CMLT) that co delivers a multi epitope citrullinated peptide (CitC) and an immunosuppressive thrombospondin‐1 (TSP‐1) plasmid via a lipid nanoparticle (LNP) platform. By rationally tuning LNP components, we achieved efficient plasmid encapsulation and stable conjugation of CitC, resulting in homogeneous nanoparticles with favorable stability. In a collagen induced arthritis (CIA) mouse model, prophylactic administration of CMLT potently suppressed disease development, significantly mitigating clinical symptoms, reducing histopathological joint damage, and preserving bone architecture. Mechanistically, CMLT fostered an immunosuppressive microenvironment marked by elevated expression of TGF‐β1 and TSP‐1, expansion of antigen specific regulatory T cells (Tregs), and suppression of autoreactive antibodies and pro inflammatory cytokines. Therapeutic intervention during active arthritis similarly alleviated inflammation and attenuated joint pathology. This synergistic nanovaccine platform provides a targeted and effective approach for re establishing immune homeostasis in RA.
Tolerogenic Nanovaccine Synergizing Citrullinated Peptide and TSP‐1 Plasmid for Antigen‐Specific Immunotherapy of Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune disorder driven by systemic inflammation and progressive joint damage. While antigen‐specific immune tolerance holds promise as a therapeutic strategy, its clinical translation is hampered by the rapid clearance and unintended immunogenicity associated with conventional antigen delivery. To address these limitations, we developed a tolerogenic nanovaccine (CMLT) that co delivers a multi epitope citrullinated peptide (CitC) and an immunosuppressive thrombospondin‐1 (TSP‐1) plasmid via a lipid nanoparticle (LNP) platform. By rationally tuning LNP components, we achieved efficient plasmid encapsulation and stable conjugation of CitC, resulting in homogeneous nanoparticles with favorable stability. In a collagen induced arthritis (CIA) mouse model, prophylactic administration of CMLT potently suppressed disease development, significantly mitigating clinical symptoms, reducing histopathological joint damage, and preserving bone architecture. Mechanistically, CMLT fostered an immunosuppressive microenvironment marked by elevated expression of TGF‐β1 and TSP‐1, expansion of antigen specific regulatory T cells (Tregs), and suppression of autoreactive antibodies and pro inflammatory cytokines. Therapeutic intervention during active arthritis similarly alleviated inflammation and attenuated joint pathology. This synergistic nanovaccine platform provides a targeted and effective approach for re establishing immune homeostasis in RA.
- 26 March 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (13) , 10724-10736
A Strand-Displacement Enabled DNA Nanomachine for Targeted St6Gal1 Silencing and Immune Reprogramming in Melanoma
Dynamic nanomachines capable of selectively engaging tumor-infiltrating immune cells and modulating their intrinsic functions represent a critical unmet need in cancer immunotherapy. Here, we develop an intelligent DNA nanomachine that selectively targets dendritic cells (DCs) within the tumor microenvironment and modulates their immunological function through regulation of prosaposin glycosylation. The nanomachine is constructed on a tetrahedral DNA nanostructure (TDN) and integrates an acid-responsive strand displacement cascade. Selective activation of this cascade in the acidic tumor microenvironment exposes a DC-SIGN-binding aptamer, thereby enabling preferential engagement with tumor-infiltrating DCs. In parallel, the nanomachine initiates RNA interference to silence St6Gal1, leading to suppression of aberrant prosaposin hyperglycosylation in melanoma-associated DCs. This spatiotemporally controlled modulation minimizes off-target interference with immune cells in normal tissues, restores the functional competence of intratumoral DCs, consequently enhances intratumoral T-cell infiltration, and markedly suppresses melanoma growth in mice. Collectively, this work establishes a programmable, strand-displacement-driven DNA nanomachine that integrates tumor microenvironment-triggered DC targeting with glycosylation-directed functional modulation, offering a generalizable strategy for precise remodeling of the tumor immune microenvironment.
- 26 March 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (13) , 10724-10736
A Strand-Displacement Enabled DNA Nanomachine for Targeted St6Gal1 Silencing and Immune Reprogramming in Melanoma
Dynamic nanomachines capable of selectively engaging tumor-infiltrating immune cells and modulating their intrinsic functions represent a critical unmet need in cancer immunotherapy. Here, we develop an intelligent DNA nanomachine that selectively targets dendritic cells (DCs) within the tumor microenvironment and modulates their immunological function through regulation of prosaposin glycosylation. The nanomachine is constructed on a tetrahedral DNA nanostructure (TDN) and integrates an acid-responsive strand displacement cascade. Selective activation of this cascade in the acidic tumor microenvironment exposes a DC-SIGN-binding aptamer, thereby enabling preferential engagement with tumor-infiltrating DCs. In parallel, the nanomachine initiates RNA interference to silence St6Gal1, leading to suppression of aberrant prosaposin hyperglycosylation in melanoma-associated DCs. This spatiotemporally controlled modulation minimizes off-target interference with immune cells in normal tissues, restores the functional competence of intratumoral DCs, consequently enhances intratumoral T-cell infiltration, and markedly suppresses melanoma growth in mice. Collectively, this work establishes a programmable, strand-displacement-driven DNA nanomachine that integrates tumor microenvironment-triggered DC targeting with glycosylation-directed functional modulation, offering a generalizable strategy for precise remodeling of the tumor immune microenvironment.
- Open Access
- 25 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Polymersomes preventing brain infiltration of CD177+ neutrophils to mitigate hemorrhagic transformation post-tPA thrombolysis
As an intravenous thrombolytic agent, tissue plasminogen activator (tPA) is limited by hemorrhagic transformation (HT) and a narrow therapeutic time window. Here we develop ROS-triggered polymersomes conjugated with fibrin-targeting CREKA peptide (CP) for tPA encapsulation. CP@tPA achieves efficient thrombosis targeting and enhanced thrombolytic efficacy, however, it has not been able to avert the occurrence of hemorrhage subsequent to thrombolysis. Building from our clinical discovery that stroke patients suffer from tPA-induced HT featured strong expression of CD177 , recombinant CD177 protein (rCD177) was loaded into CP polymersomes (CP@rCD177) as nanomedicine and administrated prior to CP@tPA thrombolysis. rCD177 can be released in response to elevated ROS within the obstructed vessels, which binds to endothelial cells through interacting with CD31 and efficiently prevents the migration of CD177 + neutrophils into the brain parenchyma. The reduced CD177 + neutrophils suppress the generation of neutrophil extracellular traps (NETs), thereby dampening the inflammatory activation of microglia and ultimately improving the prognosis of HT. This innovative strategy presents a promising avenue for attenuating hemorrhagic complications post-thrombolysis.
- 25 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessPolymersomes preventing brain infiltration of CD177+ neutrophils to mitigate hemorrhagic transformation post-tPA thrombolysis
As an intravenous thrombolytic agent, tissue plasminogen activator (tPA) is limited by hemorrhagic transformation (HT) and a narrow therapeutic time window. Here we develop ROS-triggered polymersomes conjugated with fibrin-targeting CREKA peptide (CP) for tPA encapsulation. CP@tPA achieves efficient thrombosis targeting and enhanced thrombolytic efficacy, however, it has not been able to avert the occurrence of hemorrhage subsequent to thrombolysis. Building from our clinical discovery that stroke patients suffer from tPA-induced HT featured strong expression of CD177 , recombinant CD177 protein (rCD177) was loaded into CP polymersomes (CP@rCD177) as nanomedicine and administrated prior to CP@tPA thrombolysis. rCD177 can be released in response to elevated ROS within the obstructed vessels, which binds to endothelial cells through interacting with CD31 and efficiently prevents the migration of CD177 + neutrophils into the brain parenchyma. The reduced CD177 + neutrophils suppress the generation of neutrophil extracellular traps (NETs), thereby dampening the inflammatory activation of microglia and ultimately improving the prognosis of HT. This innovative strategy presents a promising avenue for attenuating hemorrhagic complications post-thrombolysis.
- 24 March 2026
- Published by Elsevier in Biomaterials
- Vol. 332, 124156
Reversing neuroinflammation in ischemic stroke through efferocytotic phenotype reprogramming with polymeric nanoparticles
- 24 March 2026
- Published by Elsevier in Biomaterials
- Vol. 332, 124156
Reversing neuroinflammation in ischemic stroke through efferocytotic phenotype reprogramming with polymeric nanoparticles
- Open Access
- 18 March 2026
- Published by American Chemical Society (ACS) in Polymer Science & Technology
- Vol. 2 (7) , 462-481
Zwitterion-Based Polymeric Carriers for Efficient Drug Delivery across Biological Barriers
Polymeric carriers, by virtue of their tunable physicochemical properties, serve as critical platforms for drug delivery. To enhance therapeutic efficacy, considerable effort has been devoted to functionalizing polymeric carriers and exploring alternative routes of administration. However, regardless of the administration modality, polymeric carriers must overcome multiple physiological barriers during delivery. In this context, zwitterionic-rich polymeric carriers exhibit superior penetration across physiological barriers, attributable to their remarkable hydration capacity and resistance to protein adsorption. Understanding how the zwitterion structure governs barrier penetration is critical for designing drug delivery systems with enhanced tissue targeting. This review summarizes the design strategies of zwitterion-based polymeric carriers, focusing on their structure–activity relationships and mechanisms for overcoming specific physiological barriers via different administration routes. Finally, we provide perspectives on harnessing artificial intelligence for the intelligent design of zwitterion-based polymeric carriers toward their accelerated clinical translation.
- 18 March 2026
- Published by American Chemical Society (ACS) in Polymer Science & Technology
- Vol. 2 (7) , 462-481
Open AccessZwitterion-Based Polymeric Carriers for Efficient Drug Delivery across Biological Barriers
Polymeric carriers, by virtue of their tunable physicochemical properties, serve as critical platforms for drug delivery. To enhance therapeutic efficacy, considerable effort has been devoted to functionalizing polymeric carriers and exploring alternative routes of administration. However, regardless of the administration modality, polymeric carriers must overcome multiple physiological barriers during delivery. In this context, zwitterionic-rich polymeric carriers exhibit superior penetration across physiological barriers, attributable to their remarkable hydration capacity and resistance to protein adsorption. Understanding how the zwitterion structure governs barrier penetration is critical for designing drug delivery systems with enhanced tissue targeting. This review summarizes the design strategies of zwitterion-based polymeric carriers, focusing on their structure–activity relationships and mechanisms for overcoming specific physiological barriers via different administration routes. Finally, we provide perspectives on harnessing artificial intelligence for the intelligent design of zwitterion-based polymeric carriers toward their accelerated clinical translation.
- 3 February 2026
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 14 (5) , 1249-1261
tPLGA nanoparticles combined with CCL2/CCR2 inhibitor mitigate post-thrombolytic hemorrhagic transformation
An MMP-9-responsive tPLGA nanoplatform enables spatiotemporally controlled tPA delivery for targeted thrombolysis. Coupling with CCL2/CCR2 inhibition suppresses neuroinflammation, preserves BBB integrity, and prevents hemorrhagic transformation.
- 3 February 2026
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 14 (5) , 1249-1261
tPLGA nanoparticles combined with CCL2/CCR2 inhibitor mitigate post-thrombolytic hemorrhagic transformation
An MMP-9-responsive tPLGA nanoplatform enables spatiotemporally controlled tPA delivery for targeted thrombolysis. Coupling with CCL2/CCR2 inhibition suppresses neuroinflammation, preserves BBB integrity, and prevents hemorrhagic transformation.
- 7 January 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 212, 738-753
Multilayer lipid vesicles loaded with deoxyribonuclease 1 for the degradation of neutrophil extracellular traps in rheumatoid arthritis
- 7 January 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 212, 738-753
Multilayer lipid vesicles loaded with deoxyribonuclease 1 for the degradation of neutrophil extracellular traps in rheumatoid arthritis
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
Programmable immune activation and antitumor efficacy enabled by spatially encoded biomimetic framework nucleic acids
Spatially encoded DNA nanostructures with distinct 3D geometries were screened to identify an optimal architecture that enhances dendritic cell uptake, antigen presentation, and T-cell activation, thereby promoting potent antitumor immunity.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
Programmable immune activation and antitumor efficacy enabled by spatially encoded biomimetic framework nucleic acids
Spatially encoded DNA nanostructures with distinct 3D geometries were screened to identify an optimal architecture that enhances dendritic cell uptake, antigen presentation, and T-cell activation, thereby promoting potent antitumor immunity.